Our mission is to contain respiratory viruses with vaccines that activate both branches of the immune system.
Transmucosis has built the only protein-based vaccination platform that will activate both mucosal and systemic branches of the immune system.
We believe that dual immune activation will be required to contain rapidly evolving viruses like SARS-CoV-2, and other pathogens including Influenza and RSV.
Transmucosis is exploiting the unique properties of the FcRn receptor to actively transport its vaccine molecules across epithelial cell barriers.
Photo credit: CDC
The challenge for current vaccines is to keep pace with rapidly evolving viruses. Transmucosis offers promising solutions for broad protection either by combining multiple variant antigens in single vaccine, or by targeting conserved regions. Our current lead candidates are targeting either COVID-19 or influenza
